key: cord-1047334-6y3fvie7
authors: Guo, Jia; Lin, Wen-Hsuan W; Zucker, Jason E; Nandakumar, Renu; Uhlemann, Anne-Catrin; Wang, Shuang; Shivakoti, Rupak
title: Inflammation and mortality in COVID-19 hospitalized patients with and without type 2 diabetes
date: 2022-01-06
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgac003
sha: 29434a6d99f8dab0801a4e6bec7678b3fe870ed2
doc_id: 1047334
cord_uid: 6y3fvie7

BACKGROUND: The aim of this study was to determine the relationship of inflammation with mortality in COVID-19 hospitalized patients and to assess if the relationship differed by strata of type 2 diabetes status. We hypothesized that the association of inflammation with mortality was different by type 2 diabetes status. METHODS: A case-control (died-survived) study of 538 COVID-19 hospitalized patients, stratified by diabetes status, was conducted at Columbia University Irving Medical Center. We quantified the levels of eight cytokines and chemokines in serum, including interferon(IFN)-α2, IFN-γ, Interleukin(IL)-1α, IL-1β, IL-6, IL-8/CXCL8, IFNγ-induced protein 10 (IP10)/CXCL10 and tumor necrosis factor α (TNF-α) using immunoassays. Logistic regression models were used to model the relationships of log-transformed inflammatory markers (or their principal components) and mortality. RESULTS: In multiple logistic regression models, higher serum levels of IL-6 (adjusted odds ratio (aOR):1.74, 95% confidence intervals (CI): (1.48, 2.06)), IL-8 (aOR: 1.75 (1.41, 2.19)) and IP10 (aOR: 1.36 (1.24, 1.51)), were significantly associated with mortality. This association was also seen in second principal component (PC) with loadings reflecting similarities among these three markers (aOR: 1.88 (1.54-2.31)). Significant positive association of these same inflammatory markers with mortality was also observed within each strata of diabetes. CONCLUSIONS: We show that mortality in COVID19 patients is associated with elevated serum levels of innate inflammatory cytokine IL-6 and inflammatory chemokines IL-8 and IP10. This relationship is consistent across strata of diabetes, suggesting interventions targeting these innate immune pathways could potentially also benefit patients with diabetes.

A c c e p t e d M a n u s c r i p t 4

What is already know about this subject: Various inflammatory mediators have been associated with COVID-19 mortality. One of the common hypothesis is that the relationship of inflammation with COVID-19 mortality might be different by diabetes status, and this difference could help explain the increased COVID-19 mortality in this population.

What is the key question: Is the relationship of inflammation with COVID-19 mortality different by diabetes status?

What are the new findings: In a study of 538 COVID-19 hospitalized patients, we observe similar relationship of inflammatory mediators with COVID-19 mortality across strata of diabetes, when controlling for important covariates.

How might this impact on clinical practice in the foreseeable future: Our data suggests that the association of inflammation with mortality is similar among individuals with and without diabetes. As these immune mediators have therapeutic potential, our results also suggest specific immunomodulatory agents (e.g. IL-6 blockade) have the potential to also be effective among those with diabetes.

A c c e p t e d M a n u s c r i p t 5 Introduction:

Inflammation plays a major role in COVID-19 immunopathology and disease severity 1 .

SARS-CoV-2 utilizes angiotensin converting enzyme 2 (ACE2) as a receptor for entry into the host cells. ACE2 is expressed by many cell types throughout the body, including innate immune cells such as monocytes and macrophages 1 . Recognition of the virus by pathogen recognition receptors results in production of cytokines and chemokines, such as Interleukin (IL)-6, IL-1β and tumor necrosis factor α (TNFα) and interferon gamma-induced protein 10 (IP-10)/CXCL10, that are necessary to mount an effective innate immune response against SARS-CoV2 infection 2 .

However, unresolved inflammation has been linked to COVID-19 disease severity and mortality. In fact, increased cytokines (e.g., IL-6 and TNFα) and chemokines (e.g., CXCL10 and CCL2) are a hallmark of the cytokine release syndrome observed in COVID-19 3, 4 as well as SARS 5 and MERS 5, 6 . In line with this, various studies have shown that circulating levels of inflammatory cytokines, IL-6 and TNFα are higher among COVID-19 patients with more severe disease or mortality compared to those with less severe disease 3, 4, 7, 8 .

Based on these findings, various immunomodulatory agents, such as dexamethasone 9 and cytokine inhibitors 10, 11 , have been tested and shown to be among the more effective therapeutic agents against adverse COVID-19 outcomes. For example the efficacy of IL-6 blockade in improving COVID-19 outcomes, including mortality, was recently shown in the REMAP-CAP 10 and RECOVERY 11 randomized trials. However, other randomized trials have shown apparent contradictory results with no effect of IL-6 blockade on COVID-19 adverse outcomes [12] [13] [14] [15] .

The reasons for the discrepancy in effect of IL-6 as well as other immunomodulatory agents between studies are not clear 13 but of obvious clinical significance for the treatment of COVID-19 patients. One hypothesis is that differences in study population characteristics could explain the discrepancy 13 . Related to this is whether the link between inflammatory profile and mortality is the same across strata of comorbidities (e.g. type 2 diabetes status). For example, people with type 2 diabetes have dysregulated immunity even in the absence of infections, with higher levels of A c c e p t e d M a n u s c r i p t 6 inflammation compared to individuals without type 2 diabetes 16 ; but data are lacking on whether the relationship of inflammation with mortality is similar between those with and without type 2 diabetes.

If there is a difference in the relationship, the efficacy of immunomodulatory agents in COVID-19 might be different by diabetes status and would have implications for treatment strategies in this population with diabetes. Similar differences in the relationship of inflammation with mortality might also exist based on strata of other risk factors (e.g. disease severity, age, sex) and comorbidities (hypertension and obesity), as was observed for the effect of dexamethasone by disease severity 9 .

To address these research gaps, we conducted a case-control (died-survived) study of hospitalized COVID-19 patients, stratified by type 2 diabetes status. Our primary goal was to determine the association between inflammation and mortality. The secondary goal was to assess whether the association between inflammation and mortality was consistent across strata of diabetes.

Potential confounding by other risk factors was addressed by eligibility criteria (exclusion of other comorbidities), matching (disease severity and age) and covariate adjustment. Exploratory goals of this study were to determine whether the relationship of inflammation with mortality was consistent across strata of other covariates (i.e. disease severity, age, sex, body mass index, ethnicity and hypertension).

To address our primary objective of assessing the relationship of inflammation with mortality, we conducted a case-control (died-survived) study of 538 COVID-19 patients hospitalized at Inclusion criteria for this study were reverse transcription PCR-confirmed SARS-CoV2 infection, hospitalization at CUIMC for at least one day, available outcome and covariate data as well as serum samples from the CUIMC COVID-19 biobank. Exclusion criteria were those with a past medical history of type 1 diabetes, cardiovascular disease (CVD), asthma, and chronic obstructive pulmonary disease (COPD). A combination of international classification of diseases (ICD) codes was used to exclude patients meeting the exclusion criteria. The rationale for excluding these individuals was to address potential confounding by these comorbidities in answering our primary and secondary (by type 2 diabetes status) objectives.

All cases that met the eligibility criteria were selected and a random sample of matched survived controls were selected. Controls were matched to cases on age and disease severity at sampling (using the ratio of arterial oxygen partial pressure (Pao 2 ) to fractional inspired oxygen (Fio 2 )) [17] [18] [19] . Matching on age was based on decade of life. Matching on disease severity was based on the following Pao 2 :Fio 2 ratio categories: <150, 150-300, 300-400, and >400. We identified 205 cases and 333 controls, where cases were those who died and controls were those who survived.

To address our secondary objective to determine whether the relationship between inflammation and mortality was different by type 2 diabetes status, this case-control study was stratified by type 2 diabetes status (ascertained by ICD codes), with 238 patients with diabetes (58 died and 180 survived) and 300 patients without diabetes (147 died and 153 survived). Data on other relevant variables, including age, sex, ethnicity, disease severity, body mass index (BMI), known type 2 diabetes, laboratory data for random glucose and HbA1c, diabetes medications, and known status for hypertension, cancer, chronic kidney disease, chronic liver disease and HIV were obtained from patient medical records.

A c c e p t e d M a n u s c r i p t 8

This study was approved by the Institutional Review Board (IRB) at Columbia University.

All guidelines for human experimentation from the US Department of Health and Human Services were followed.

Serum samples were collected from patients using standardized procedures as part of the CUIMC COVID-19 biobank and stored in -80ºC until further use. For this study, we selected the earliest available serum sample from each patient. We measured levels of IFN-α2, IFN-γ, IL1-α, IL-1β, IL-6, IL-8, IP-10 and TNF-α in duplicate samples using multiplex Luminex immunoassays following the manufacturer's directions (Catalog # HCYTA-60K from Millipore Sigma; RRID: AB_2895156). The range of detection was 8-125,000 pg/mL for IFN-α2, 1.3-20,000 for IFN-γ, 8-75,000 pg/mL for IL-1α, 1.6-25,000 pg/mL for IL1β, 0.64-10,000 pg/mL for IL-6 and IL-8, 2.6-40,000 pg/mL for IP-10 and 6.4-100,000 pg/mL for TNFα. These immune mediators were chosen based on their association with mortality in other studies 3, 4, 7, 8 , and were measured at the Biomarkers Core Laboratory, Irving Institute for Clinical and Translational Research at CUIMC.

The primary analysis examined the association between mortality and each log-transformed inflammatory marker. We first conducted simple logistic regression models and then multiple logistic regression models adjusting for age, disease severity, gender, ethnicity, body mass index (BMI), hypertension status and type 2 diabetes status. Additional models also further adjusted for date of sample collection. We used FDR (false discovery rate) <0.05 as the threshold for significance to adjust for multiple comparisons of 8 immune mediators. To further investigate association between mortality and correlation of multiple immune mediators, we conducted principal components analysis A c c e p t e d M a n u s c r i p t 9 (PCA) on the 8 immune mediators and logistic regression models on the first two principal components (PC1 and PC2 with an eigenvalue>1) examining their association with mortality adjusting for the same aforementioned covariates.

In the secondary analysis, we tested whether the association between inflammation and mortality was different by diabetes status. For each immune mediator, we tested the interaction between diabetes status and biomarker measures (each marker and two PCs) in a logistic regression model adjusting for age, disease severity, sex, ethnicity, body mass index (BMI) and hypertension status. Further, we also conducted analysis to test if the individual markers and first two PCs were associated with mortality within each strata of type 2 diabetes. We also explored the association between the first two PCs and mortality in additional logistic regression models adjusting for other comorbidities including cancer, chronic kidney disease, chronic liver disease and HIV in the entire cohort and within strate of type 2 diabetes. For models of individuals within the diabetes strata, we also adjusted for glucose/HbA1c and metformin. In addition, we conducted exploratory analyses testing if the first two PCs were associated with mortality within each strata of the following risk factors: 1) disease severity, 2) age, 3) BMI, 4) sex, 5) ethnicity, and 6) hypertension. For each of these analyses, we adjusted for the other covariates. All statistical analyses were conducted in R version 4.0.2 (2020-06-22). A c c e p t e d M a n u s c r i p t 10 51%). Cases had more severe disease based on Pao 2 :Fio 2 ratio and lower proportion of hypertension (25% vs. 42%). In line with the first wave of the pandemic in New York City, the majority (73%) of cases and controls had samples collected in April 2020.

The means (SDs) of the 8 log-transformed inflammatory mediators are summarized in Supplementary Table 1 Table 2 also provides ORs and p-values for associations between mortality and each log-transformed inflammatory marker from logistic regressions adjusting for age, disease severity, gender, ethnicity, BMI, hypertension status, and type 2 diabetes status. It shows that log-IL6, log-IL8 and log-IP10 are still significantly associated with mortality after FDR correction (BH-adjusted p<0.01), with odds ratio 1.53 (1.29-1.85), 1.82 (1.43-2.36), and 1.28 (1.14-1.44), respectively. The results were similar in models further adjusting for date of sample collection (data not shown).

We next address our secondary objective on whether the association between mortality and inflammation was different by type 2 diabetes status. In multiple logistic regression models of the combined population with and without type 2 diabetes, there were no significant interactions between diabetes status and any inflammatory markers after adjusting for age, disease severity, gender, ethnicity, BMI and hypertension status (data not shown). We further conducted stratified analyses by Table 2 20 displays means (SDs) of the three identified markers stratified by diabetes and mortality status. Logistic regression analysis results stratified by type 2 diabetes status is summarized in Table 3 . Among patients without DM, there are significant associations between mortality and log-IL6, log-IL8 and log-IP10 (BH-adjusted p<0.01), which are consistent with the results on the entire cohort. Among patients with type 2 diabetes, no significant associations are observed after FDR correction, likely due to the smaller sample size.

However, we noticed that although these three inflammatory mediators are not statistically significant among patients with type 2 diabetes, the effect estimates were similar and in the same direction as in the entire cohort. Therefore, we conducted PCA analysis within patients with type 2 diabetes, within patients without type 2 diabetes, and within the entire cohort, respectively. Loadings of the first two principal components (PCs) are summarized in Supplementary Table 3 Table 4 shows the association results between mortality and the first PC, and the second PC separately. The first PC is not associated with mortality in any of the three cohorts as expected, as PC1 simply averaged the 8 markers with the same-direction-loading. The second PC, which can be considered as an aggregated effect of the three markers, log-IL6, log-IL8 and log-IP10, were associated with mortality after adjusting for covariates in both patients with and without DM, as well as the combined cohort, with odds ratio 1.79 (1. 26 

As the immune profile is known to differ by factors such as disease severity, age, BMI or sex, we next conducted several exploratory analyses examining whether the observed relationship of mortality and inflammation were consistent across strata of other COVID-19 mortality risk factors.

For example, is the relationship of inflammation with mortality consistent among those with more severe as compared to less severe disease? To explore these questions, we conducted stratified analysis of the PCs with mortality, adjusting for the other covariates including diabetes, across strata of disease severity (Pao 2 :Fio 2 ratio categories: <300 and ≥300). We observed that PC2, with high loadings of IL6, IL8 and IP10, was significantly (p<0.05) associated with mortality in each of four strata of disease severity. We conduced similar analysis (i.e. separate analysis for each risk factor) across the strata of age (<70 and ≥70), BMI (obese and not obese), sex, ethnicity, and hypertension status (Supplementary Table 4 20 ). PC2 in each of these strata had a similar profile with high loadings of IL6, IL8 and IP10. The positive and significant association of PC2 with mortality was consistent across the different strata of each of these various risk factors (Supplementary Table 4 We assessed the relationship of inflammation with mortality in COVID-19 hospitalized patients in this study, and observed that serum level of three innate cytokine and chemokines, IL6, IL8 and IP10 were associated with mortality. Importantly, our results suggest that there is no interaction by type 2 diabetes status; this positive and significant association between inflammation and mortality was consistent across strata of diabetes as well as other risk factors, including disease severity, age and BMI. These results suggested that dysregulated innate immune response may play an important role in COVID-19 mortality, regardless of diabetes and other risk factor strata. Thus, immunomodulatory therapeutics such as IL-6 inhibitors have the potential to reduce mortality in populations with and without comorbidities. If future interventional studies should confirm this, it would have direct implications for treatment management of COVID-19 patients.

Among the 8 markers assessed in this study, only three markers of IL6, IL8 and IP10 were associated with mortality. We had selected the 8 markers (TNFα, IL1α, IL1β, IFNα2 and IFNγ in addition to the other markers) based on prior studies of COVID-19 patients that had shown an association of these markers with severe disease or mortality 3, 4, 7, 8, [21] [22] [23] . A likely reason for the differences in findings between our study and other studies is our unique study population. In order to remove the potential confounding role of various comorbidities, our study specifically excluded individuals with type 1 diabetes, CVD, asthma and COPD. It is possible that some of these additional markers are associated with the comorbidities rather than mortality itself; alternatively, the association of these markers with mortality might be different in the presence of these comorbidities. Our conclusions are thus based on a population of hospitalized with and without type 2 diabetes, but who do not have these comorbidities. Further, we also matched and accounted for important covariates, such as disease severity, older age and obesity, which themselves can impact inflammation and mortality.

An association between increased serum IL6, IL8 and IP10 with mortality has been noted in multiple studies 21, 22 , and our results further confirm the role of these mediators in populations without A c c e p t e d M a n u s c r i p t 14 COPD, CVD, asthma and type 1 diabetes, and also when controlling for disease severity, age and other important risk factors. The IL-6 blockade interventional studies suggest that IL-6 plays a causal role in mortality at least in certain settings 10, 13 . In addition, we also noted IL-8 and IP-10 were also associated with mortality. IL-8 is pro-inflammatory chemokine produced by macrophages and other cells, and is involved in recruiting and activating neutrophils 24 . IL-8 could directly contribute to the increased levels of neutrophils observed in COVID-19, with higher levels resulting in increased mortality 21 . IP10 is IFN-γ inducible protein produced by various immune cells including macrophages, T cells and dendritic cells and has pro-inflammatory and anti-angiogenic functions 25 .

Related to COVID-19, studies suggest that early on IP-10 has an important role in viral clearance while unresolved high levels could contribute to immunopathology, including acute lung injury 26 .

Given the high loadings of IL6, IL8 and IP-10 in PCA analysis, these markers might potentially share a common mechanism or pathway that is contributing to mortality and will need to be studied further.

While studies have assessed the relationship of inflammation with mortality, studies are lacking on whether this relationship is different across strata of type 2 diabetes. Our results on type 2 diabetes suggest that there is no interaction by diabetes status in the relationship between inflammation and mortality. Both formal interaction tests and results from the stratified analysis confirmed this. Potential differences in the relationship of inflammation with mortality by type 2 diabetes status could have meant that different anti-inflammatory agents or different doses might need to be utilized for those with diabetes compared to those without diabetes. However, our results do not support the hypothesized role of diabetes status in impacting the relationship of inflammation with mortality, and providing the biological mechanism to explain the increased mortality associated with type 2 diabetes 16 . Of note, the results from individual analysis of each marker in stratified analysis among those with type 2 diabetes were not significant but it was likely due to multiple comparison adjustments in a smaller sample size; our PCA analysis supports this where PC2, with high loadings of IL6, IL8 and IP10, was associated with mortality within both strata of diabetes. These results were also confirmed in models that adjusted for glucose levels. We should note that our stratified analysis was designed and our findings are applicable to the overall populations; we did not have the A c c e p t e d M a n u s c r i p t 15 appropriate power to further assess whether among those with type 2 diabetes, there were difference by additional strata of diabetes-specific risk factors such as glucose control, duration of diabetes or diabetes medications 16 .

In addition to diabetes, we also explored whether the relationship of inflammation with mortality differed by other risk factors. For example, inflammation is known to be different by disease severity, obesity, age, sex and other comorbidities (e.g. hypertension) 21, 27, 28 , thus inflammation could potentially have a different relationship with mortality within strata of these risk factors. However, our exploratory results showed a consistent and positive association of these same markers (i.e. PC2) with mortality within each of the strata of these risk factors. As with diabetes, we did not have the power to further look at additional strata (e.g. hypertensive medications) of risk factors. Regardless, these findings suggest a strong relationship of inflammation with mortality that is consistent across strata. While our results suggest that these pathways are theoretically relevant targets (i.e. there is an association) to reduce mortality, regardless of additional risk factors, this will have to be confirmed by well-designed interventional studies (e.g. using IL-6 inhibitors) conducted across different strata of risk factors. Regarding discrepancy between studies of IL-6 inhibitors [12] [13] [14] [15] , it is possible that other factors (e.g. specific product, dose or duration, or timing of the intervention rather than these study population characteristics) could explain the results; alternatively despite the association across strata, it is possible that the intervention is less effective in certain strata (e.g. very advanced disease).

Limitations of this study were smaller sample sizes within strata of risk factors (e.g. glucose control and diabetes), lack of generalizability to populations with CVD, asthma, type 1 diabetes and COPD, focus on limited number of immune markers that were only pro-inflammatory, and conduct of the study in a pandemic setting with challenges in data collection (e.g. missing data for HbA1c or quality of medication data). It is also not clear whether our data from earlier in the pandemic would be as generalizable to more recent times given advances in treatment. Our study also has multiple strengths. One is related to the eligibility criteria and study design that addresses potential confounding by comorbidities, disease severity and other risk factors. Our sample size was adequate for both the primary and secondary questions. We assessed multiple markers of inflammation that are A c c e p t e d M a n u s c r i p t 16 relevant in the context of COVID-19, and linked them to well-characterized clinical and mortality data.

In conclusion, our study showed that three immune markers of IL6, IL8 and IP10 were linked with mortality, with consistent and positive associations through strata of type 2 diabetes and other risk factors. Our results support existing efforts to target these pathways and provide supportive data to suggest that the interventions may be effective across strata of diabetes and other risk factors;

future interventional studies will need to confirm this. M a n u s c r i p t 20 M a n u s c r i p t 21 A c c e p t e d M a n u s c r i p t 22 A c c e p t e d M a n u s c r i p t 23 M a n u s c r i p t 

Cytokine release syndrome in severe COVID-19

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine

Interleukin-6 Receptor Inhibition in Covid-19 -Cooling the Inflammatory Soup. The New England journal of medicine

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

Type 2 diabetes as an inflammatory disease

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England journal of medicine

Nonlinear Imputation of PaO2/FIO2 From SpO2/FIO2 Among Mechanically Ventilated Patients in the ICU: A Prospective, Observational Study. Critical care medicine

Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome

Inflammation and mortality in COVID-19 hospitalized patients with and without type 2 diabetes

An inflammatory cytokine signature predicts COVID-19 severity and survival

Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm? Front

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils

CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet

Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19

Sex differences in immune responses that underlie COVID-19 disease outcomes

Mechanism of inflammatory response in associated comorbidities in COVID-19

A c c e p t e d M a n u s c r i p t 18